CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
CNS Pharmaceuticals (NASDAQ:CNSP) announces a Virtual Analyst & Investor Day scheduled for December 11th, 2024, from 11:30 AM to 1:00 PM ET. The event will feature discussions on Glioblastoma Multiforme (GBM), an aggressive brain cancer with only 14-16 months average survival post-diagnosis.
The presentation will include key company executives and renowned medical experts: CEO John Climaco, CMO Sandra Silberman, VP of Clinical Operations Zena Muzyczenko, along with KOLs Michael Weller, Samuel Goldlust, and Erin Dunbar.
The agenda includes an overview of Berubicin and its clinical development program, plus discussion of their second asset, TPI 287. The event will be accessible via webcast on the company's website, with replay available for 90 days.
CNS Pharmaceuticals (NASDAQ:CNSP) annuncia un Analyst & Investor Day Virtuale programmato per l'11 dicembre 2024, dalle 11:30 alle 13:00 ET. L'evento presenterà discussioni su Glioblastoma Multiforme (GBM), un cancro al cervello aggressivo con una sopravvivenza media di soli 14-16 mesi dopo la diagnosi.
La presentazione includerà dirigenti chiave dell'azienda e esperti medici di fama: il CEO John Climaco, il CMO Sandra Silberman, il VP delle Operazioni Cliniche Zena Muzyczenko, insieme ai KOL Michael Weller, Samuel Goldlust ed Erin Dunbar.
L'agenda include una panoramica di Berubicin e del suo programma di sviluppo clinico, oltre a una discussione sul loro secondo asset, TPI 287. L'evento sarà accessibile tramite webcast sul sito web dell'azienda, con replay disponibile per 90 giorni.
CNS Pharmaceuticals (NASDAQ:CNSP) anuncia un Día Virtual de Analistas e Inversores programado para el 11 de diciembre de 2024, de 11:30 AM a 1:00 PM ET. El evento incluirá discusiones sobre glioblastoma multiforme (GBM), un cáncer de cerebro agresivo con una supervivencia media de solo 14-16 meses después del diagnóstico.
La presentación contará con importantes ejecutivos de la empresa y reconocidos expertos médicos: el CEO John Climaco, la CMO Sandra Silberman, la VP de Operaciones Clínicas Zena Muzyczenko, junto con los KOLs Michael Weller, Samuel Goldlust y Erin Dunbar.
La agenda incluye una visión general de Berubicin y su programa de desarrollo clínico, además de una discusión sobre su segundo activo, TPI 287. El evento será accesible a través de una transmisión en vivo en el sitio web de la empresa, con una repetición disponible durante 90 días.
CNS Pharmaceuticals (NASDAQ:CNSP)는 2024년 12월 11일 오전 11시 30분부터 오후 1시까지 ET로 예정된 가상 애널리스트 및 투자자 데이를 발표했습니다. 이번 행사에서는 다형성 교모세포종 (GBM), 즉 진단 후 평균 생존 기간이 단 14-16개월인 공격적인 뇌암에 대한 논의가 있을 예정입니다.
프레젠테이션에는 회사의 주요 임원들과 저명한 의학 전문가들이 참석합니다: CEO John Climaco, CMO Sandra Silberman, 임상 운영 부사장 Zena Muzyczenko, 그리고 KOL Michael Weller, Samuel Goldlust 및 Erin Dunbar이 함께합니다.
의제에는 Berubicin의 개요와 임상 개발 프로그램에 대한 설명이 포함되며, 두 번째 자산인 TPI 287에 대한 논의도 포함됩니다. 이 행사는 회사 웹사이트를 통해 웹캐스트로 제공되며, 90일 동안 다시 볼 수 있습니다.
CNS Pharmaceuticals (NASDAQ:CNSP) annonce une Journée Virtuelle des Analystes et des Investisseurs prévue pour le 11 décembre 2024, de 11h30 à 13h00 ET. L'événement comprendra des discussions sur le glioblastome multiforme (GBM), un cancer du cerveau agressif avec une survie moyenne de seulement 14 à 16 mois après le diagnostic.
La présentation inclura des dirigeants clés de l'entreprise et des experts médicaux renommés : le PDG John Climaco, la CMO Sandra Silberman, la VP des opérations cliniques Zena Muzyczenko, ainsi que les KOLs Michael Weller, Samuel Goldlust et Erin Dunbar.
L'agenda comprend un aperçu de Berubicin et de son programme de développement clinique, ainsi qu'une discussion sur leur deuxième actif, TPI 287. L'événement sera accessible via un webinaire sur le site internet de l'entreprise, avec une rediffusion disponible pendant 90 jours.
CNS Pharmaceuticals (NASDAQ:CNSP) gibt einen virtuellen Analysten- und Investorentag bekannt, der für den 11. Dezember 2024 von 11:30 bis 13:00 Uhr ET geplant ist. Die Veranstaltung wird Diskussionen über Multiformes Glioblastom (GBM) beinhalten, eine aggressive Form von Hirnkrebs mit einer durchschnittlichen Überlebensdauer von nur 14-16 Monaten nach der Diagnose.
Die Präsentation wird wichtige Führungskräfte des Unternehmens und renommierte medizinische Experten umfassen: CEO John Climaco, CMO Sandra Silberman, VP der klinischen Operationen Zena Muzyczenko sowie die KOLs Michael Weller, Samuel Goldlust und Erin Dunbar.
Die Agenda umfasst einen Überblick über Berubicin und sein klinisches Entwicklungsprogramm sowie eine Diskussion über deren zweiten Vermögenswert, TPI 287. Die Veranstaltung wird über einen Webcast auf der Unternehmenswebsite zugänglich sein, mit einer Wiederholung, die 90 Tage verfügbar ist.
- None.
- None.
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders
Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure
Register for the event here
HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET.
For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zurich, Switzerland; Samuel Goldlust, MD, Board-certified and fellowship-trained neuro oncologist with Saint Luke's Cancer Specialists; and Erin Dunbar, MD founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital.
As part of the event, the members of the CNS Pharmaceuticals management team and participating KOLs will discuss GBM and provide an overview of Berubicin and next steps for the clinical development program. Additionally, participants will discuss the Company's second asset, TPI 287, and its development and regulatory strategy moving forward.
A live video webcast of the event will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When is CNS Pharmaceuticals (CNSP) hosting its Virtual Analyst & Investor Day?
What treatments is CNSP developing?
Who are the key speakers at CNSP's Virtual Analyst & Investor Day?
How long will the CNSP Virtual Analyst Day webcast replay be available?
